Roivant Sciences ROIV
NASDAQ ROIV
$39.63 -0.14 (-0.34%)
As of: Sep 21, 2026 · 10:57 AM EDT

Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026)

Roivant Sciences' (ROIV) quarterly Income from Non-Controlling Interests came in at -$100.8 million in Q2 2026, down 99.32% on a YoY basis from -$14.9 billion in Q2 2025, and up 33.22% quarter-over-quarter from -$150.9 million in Q4 2025.

Analysis

Roivant Sciences (ROIV) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends

Roivant Sciences (ROIV) has reported Income from Non-Controlling Interests for 7 consecutive years, with -$100.8 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Income from Non-Controlling Interests fell 99.32% year-over-year to -$100.8 million; the trailing twelve-month figure through Jun 2026 stood at -$354.7 million (down 28.08% YoY), and the FY2026 full-year result was -$98.1 million, up 46.88% from the prior year.
  • Income from Non-Controlling Interests advanced to -$100.8 million in Q2 2026 per ROIV's latest filing, from -$150.9 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at -$22.0 million in Q2 2022 and bottomed at -$150.9 million in Q4 2025.
  • Historically, Income from Non-Controlling Interests has averaged -$65.8 million across 5 years, with a median of -$50.6 million in 2025.
  • The sharpest annual moves came in 2024 and 2026: Income from Non-Controlling Interests declined 4.93% in 2024, then slumped 99.32% in 2026.
  • Over 5 years, Income from Non-Controlling Interests stood at -$79.2 million in 2022, then fell by 9.03% to -$86.3 million in 2023, then sank by 60.82% to -$138.9 million in 2024, then retreated by 8.67% to -$150.9 million in 2025, then jumped by 33.22% to -$100.8 million in 2026.
  • According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$100.8 million, -$150.9 million, and -$52.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Amgen 208.48 Bn 194.49 Bn 7.24 Bn -
2 Gilead Sciences 186.29 Bn 183.02 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 128.79 Bn 120.93 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 80.66 Bn 72.67 Bn 3.93 Bn -
5 Moderna 61.46 Bn 56.32 Bn 52.00 Mn -
6 Argenx Se 61.28 Bn 56.10 Bn 1.37 Bn -
7 Alnylam Pharmaceuticals 32.04 Bn 28.73 Bn 992.69 Mn -
8 Biogen 31.84 Bn 30.56 Bn 1.96 Bn -
9 Roivant Sciences 28.74 Bn 29.43 Bn 1.16 Mn -100.77 Mn
10 Insmed 26.19 Bn 25.03 Bn 358.27 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -100.77 Mn
Dec 31, 2025 -150.89 Mn
Sep 30, 2025 -52.52 Mn
Jun 30, 2025 -50.56 Mn
Dec 31, 2024 -138.85 Mn
Sep 30, 2024 -49.74 Mn
Jun 30, 2024 -37.81 Mn
Dec 31, 2023 -86.34 Mn
Sep 30, 2023 -26.79 Mn
Jun 30, 2023 -36.03 Mn
Dec 31, 2022 -79.19 Mn
Sep 30, 2022 -24.33 Mn
Jun 30, 2022 -21.98 Mn
Dec 31, 2021 -57.60 Mn
Sep 30, 2021 -17.16 Mn
Jun 30, 2021 -18.90 Mn
Dec 31, 2020 -14.57 Mn
Sep 30, 2020 -18.10 Mn
Jun 30, 2020 -4.73 Mn